Diagnostics

IMPATH announces distribution agreement for QCA system

Published in Immunotherapy Weekly, April 14th, 2004

IMPATH, Inc., (IPK) announced that it has entered into an agreement with Cell Analysis under which IMPATH will provide Cell Analysis' quantitative cellular assessment (QCA) system exclusively to IMPATH's clients.

IMPATH anticipates launching the QCA system in the marketplace early in the second quarter of 2004. Specific terms of the agreement were not disclosed.

Cell Analysis' QCA system has received FDA (U.S. Food and Drug Administration) clearance for estrogen receptor markers in breast cancer and is expected to receive clearance for the oncoprotein, Her2/neu, later in 2004. In addition, the system has been designed to analyze all nuclear,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2004-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry